Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2015

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon beta-1a

Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.

Trial Locations (17)

1200

Research Site, Woluwe

1340

Research Site, Ottignies

2020

Research Site, Middelheim

2820

Research Site, Bonheiden

3500

Research Site, Hasselt

4000

Research Site, Liège

4800

Research Site, Verviers

6000

Research Site, Charleroi

6042

Research Site, Charleroi

6800

Research Site, Libramont

7100

Research Site, La Louvière

7331

Research Site, Baudour

7500

Research Site, Tournai

8340

Research Site, Sijsele

8700

Research Site, Tielt

9100

Research Site, Saint Niklaas

9300

Research Site, Aalst

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY